https://mindmedicinelaw.com/briefing/phase-2-psilocybin-trial-for-major-depression-u-s-launch-2027-20260910-40731The Psychedelic Journalen2026-09-10T22:04:23.420512+00:00Phase 2 Psilocybin Trial for Major Depression: U.S. Launch 2027psilocybin, clinical trials, major depressive disorder, phase 2, FDA, psychedelic therapy, mental health, regulatory policy, adverse events, efficacyhttps://mindmedicinelaw.com/briefing/compass-pathways-taps-fluence-for-comp360-psilocybin-provider-training-20260910-40734The Psychedelic Journalen2026-09-10T22:04:10.637430+00:00Compass Pathways Taps Fluence for COMP360 Psilocybin Provider Trainingcompass pathways, fluence, comp360, psilocybin therapy, provider training, fda rems, treatment-resistant depression, psychedelic workforce, clinical adoption, regulatory approvalhttps://mindmedicinelaw.com/briefing/fda-signals-openness-to-innovative-psychedelic-drug-development-20260910-40732The Psychedelic Journalen2026-09-10T22:03:54.891472+00:00FDA Signals Openness to Innovative Psychedelic Drug Developmentfda psychedelic policy, psychedelic clinical trials, drug development innovation, regulatory guidance psychedelics, mdma approval process, psilocybin research, adaptive trial design, expanded access programs, psychedelic therapy riskshttps://mindmedicinelaw.com/briefing/optimi-health-s-phase-2-psilocybin-trial-for-depression-canada-s-next-step-20260910-40566The Psychedelic Journalen2026-09-10T15:07:33.007936+00:00Optimi Health’s Phase 2 Psilocybin Trial for Depression: Canada’s Next Stepoptimi health, psilocybin trial, major depressive disorder, canada clinical trials, health canada, psychedelic-assisted therapy, phase 2 trial, regulatory pathways, mental health researchhttps://mindmedicinelaw.com/briefing/clinician-training-for-comp360-psilocybin-u-s-certification-program-emerges-20260910-40567The Psychedelic Journalen2026-09-10T15:07:01.222290+00:00Clinician Training for COMP360 Psilocybin: U.S. Certification Program Emergescomp360, psilocybin therapy, clinician training, fda approval, certificate program, psychedelic-assisted therapy, clinical infrastructure, treatment-resistant depression, standardization, regulatory policyhttps://mindmedicinelaw.com/briefing/epik-biosciences-ketamine-dxm-patent-filings-implications-for-psychedelic-ip-in--20260910-40568The Psychedelic Journalen2026-09-10T15:06:40.476078+00:00EPIK Biosciences' Ketamine/DXM Patent Filings: Implications for Psychedelic IP in Asia-Pacificepik biosciences, ketamine, dextromethorphan, provisional patent, psychedelic ip, combination medicines, asia-pacific, clinical trials, regulatory policy, patent thickethttps://mindmedicinelaw.com/briefing/two-threshold-model-for-psilocybin-response-in-trd-research-implications-20260909-40321The Psychedelic Journalen2026-09-09T22:06:11.723854+00:00Two-Threshold Model for Psilocybin Response in TRD: Research Implicationspsilocybin, treatment-resistant depression, two-threshold model, clinical trial design, patient selection, biomarkers, psychedelic-assisted therapy, response variability, regulatory policyhttps://mindmedicinelaw.com/briefing/psilocybin-and-mood-disorders-real-world-data-and-u-s-policy-implications-20260909-40403The Psychedelic Journalen2026-09-09T22:05:59.691812+00:00Psilocybin and Mood Disorders: Real-World Data and U.S. Policy Implicationspsilocybin, mood disorders, real-world data, clinical trials, FDA policy, psychedelic research, mental health, regulatory implications, observational studieshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-veterans-pilot-study-signals-safety-potential-in-u-s-20260909-40402The Psychedelic Journalen2026-09-09T22:05:02.873198+00:00Psilocybin Therapy for Veterans: Pilot Study Signals Safety, Potential in U.S.psilocybin, veterans, ptsd, pilot study, psychedelic therapy, clinical trials, safety, fda regulation, policy, u.s. department of veterans affairshttps://mindmedicinelaw.com/briefing/compass-pathways-1-year-psilocybin-data-implications-for-u-s-policy-20260909-40401The Psychedelic Journalen2026-09-09T22:04:38.496072+00:00Compass Pathways' 1-Year Psilocybin Data: Implications for U.S. Policycompass pathways, psilocybin therapy, treatment-resistant depression, phase 3 clinical trial, fda review, payer policy, psychedelic medicine, long-term efficacy, mental health, regulatory approvalhttps://mindmedicinelaw.com/briefing/fda-public-hearing-signals-evolving-psychedelic-policy-in-the-us-20260909-40237The Psychedelic Journalen2026-09-09T15:05:07.223011+00:00FDA Public Hearing Signals Evolving Psychedelic Policy in the USfda hearing, psychedelic policy, therapeutic psychedelics, clinical trials, regulatory guidance, dr angela fisher, us drug policy, public health, risk assessment, stakeholder engagementhttps://mindmedicinelaw.com/briefing/legal-psilocybin-sessions-and-mental-health-early-outcomes-and-policy-implicatio-20260909-40238The Psychedelic Journalen2026-09-09T15:04:49.478083+00:00Legal Psilocybin Sessions and Mental Health: Early Outcomes and Policy Implicationspsilocybin, legal psychedelic services, mental health outcomes, policy implications, public health, clinical trial design, oregon psilocybin law, risk management, evidence gapshttps://mindmedicinelaw.com/briefing/anti-nmdar1-autoantibodies-and-psychiatric-outcomes-after-tbi-implications-for-g-20260908-40334The Psychedelic Journalen2026-09-10T15:08:57.166889+00:00Anti-NMDAR1 Autoantibodies and Psychiatric Outcomes After TBI: Implications for Glutamatergic Researchanti-nmdar1 autoantibodies, traumatic brain injury, depression, ptsd, glutamatergic modulation, biomarkers, psychiatric resilience, ketamine, clinical trials, neuroprotectionhttps://mindmedicinelaw.com/briefing/habenular-transcriptomics-illuminate-depression-subtypes-in-mice-20260908-40451The Psychedelic Journalen2026-09-10T15:08:36.013753+00:00Habenular Transcriptomics Illuminate Depression Subtypes in Micehabenula, single-cell rna sequencing, depression subtypes, mouse model, transcriptomics, precision psychiatry, psychedelic therapeutics, stress resilience, cell-type specificity, neurosciencehttps://mindmedicinelaw.com/briefing/gut-microbiota-inflammation-brain-axis-in-mdd-multi-omics-evidence-20260908-40504The Psychedelic Journalen2026-09-10T15:08:14.356849+00:00Gut Microbiota-Inflammation-Brain Axis in MDD: Multi-Omics Evidencegut microbiota, major depressive disorder, inflammation, multi-omics, brain connectivity, biomarkers, psychedelic research, clinical trials, neuroinflammationhttps://mindmedicinelaw.com/briefing/lsd-analogues-with-enhanced-safety-new-findings-from-ergolog-research-20260908-40491The Psychedelic Journalen2026-09-10T15:05:58.707186+00:00LSD Analogues With Enhanced Safety: New Findings From Ergolog Researchlsd analogues, ergologs, 5-ht2c agonists, psychedelic safety, drug development, clinical trials, receptor selectivity, u.s. fda, neuropsychiatric therapeutics, psychedelic regulationhttps://mindmedicinelaw.com/briefing/mystical-experiences-predict-ocd-improvement-after-psilocybin-20260908-40452The Psychedelic Journalen2026-09-10T15:05:21.321063+00:00Mystical Experiences Predict OCD Improvement After Psilocybinpsilocybin, ocd, mystical experience, clinical trial, psychedelic therapy, treatment-resistant, subjective experience, regulatory policy, integration, set and settinghttps://mindmedicinelaw.com/briefing/sge-301-modulates-rtms-induced-plasticity-implications-for-neuropsychiatric-rese-20260908-40335The Psychedelic Journalen2026-09-09T22:06:22.783428+00:00SGE-301 Modulates rTMS-Induced Plasticity: Implications for Neuropsychiatric Researchsge-301, rTMS, neuroplasticity, nmda receptor, ltp, psychedelic research, preclinical study, combination therapy, translational neuroscience, clinical trial designhttps://mindmedicinelaw.com/briefing/psilocybin-and-repetitive-mild-head-injury-new-preclinical-evidence-20260908-40286The Psychedelic Journalen2026-09-09T22:05:25.882552+00:00Psilocybin and Repetitive Mild Head Injury: New Preclinical Evidencepsilocybin, traumatic brain injury, neuroinflammation, tau pathology, neuroplasticity, preclinical research, clinical trial design, public health, psychedelic therapyhttps://mindmedicinelaw.com/briefing/psychedelics-as-neuroregenerative-agents-cns-repair-evidence-and-gaps-20260908-40322The Psychedelic Journalen2026-09-09T22:05:14.475390+00:00Psychedelics as Neuroregenerative Agents: CNS Repair Evidence and Gapspsychedelics, neuroregeneration, psychoplastogens, central nervous system repair, clinical trials, neuroplasticity, 5-HT2A receptor, bdnf, regulatory policy, translational researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-ptsd-meta-analysis-signals-efficacy-highlights-gaps-20260908-40306The Psychedelic Journalen2026-09-09T22:04:48.992182+00:00MDMA-Assisted Therapy for PTSD: Meta-Analysis Signals Efficacy, Highlights Gapsmdma-assisted therapy, ptsd treatment, systematic review, meta-analysis, psychedelic clinical trials, regulatory pathways, sponsor bias, functional disability, public health policyhttps://mindmedicinelaw.com/briefing/revisiting-early-psychedelic-therapy-trials-us-canada-1965-1977-20260907-40326The Psychedelic Journalen2026-09-09T22:05:49.894822+00:00Revisiting Early Psychedelic Therapy Trials: US & Canada, 1965–1977psychedelic therapy, clinical trial design, durable effects, regulatory standards, patient selection, mystical experience, afterglow, psychotherapy integration, FDA, historical trialshttps://mindmedicinelaw.com/briefing/post-trial-duties-in-neurosurgical-device-research-policy-and-ethics-in-focus-20260907-40325The Psychedelic Journalen2026-09-09T22:05:39.116763+00:00Post-Trial Duties in Neurosurgical Device Research: Policy and Ethics in Focuspost-trial responsibility, neurosurgical device trials, psychedelic research, clinical ethics, regulatory policy, participant care, implantable neurotechnologies, institutional review boards, FDA guidance, long-term supporthttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-therapy-for-trauma-policy-and-clinical-implications-20260904-40240The Psychedelic Journalen2026-09-09T15:04:33.556980+00:00New Zealand Approves MDMA Therapy for Trauma: Policy and Clinical Implicationsmdma therapy, new zealand policy, psychedelic regulation, trauma care, asia-pacific, clinical trials, mental health, public health policy, psychedelic medicinehttps://mindmedicinelaw.com/briefing/ethical-challenges-in-mdma-assisted-therapy-trials-for-ptsd-20260901-40479The Psychedelic Journalen2026-09-10T15:07:53.053729+00:00Ethical Challenges in MDMA-Assisted Therapy Trials for PTSDmdma-assisted therapy, ptsd, clinical trials, ethics, informed consent, therapist-patient boundaries, regulatory approval, risk monitoring, therapist training